News about "Antibody Drug Conjugate (ADC) "

GlycoNex Doses First Patient in Phase 1 Trial of GNX1021

GlycoNex dosed the first patient in its phase 1 trial of GNX1021, advancing its glycan-directed Antibody Drug Conjugate (ADC) while exploring global licensing and co-development deals.

Antibody Drug Conjugate (ADC) | 03/08/2026 | By News Bureau

Jideytro Wins US Approval for ROS1-Positive NSCLC

Jideytro (zidesamtinib) has won US approval for previously treated ROS1-positive NSCLC, backed by ARROS-1 trial results showing durable responses.

Antibody Drug Conjugate (ADC) | 24/07/2026 | By News Bureau |  107

US FDA Approves PADCEV Plus Keytruda for Muscle-Invasive Bladder Cancer

The US Food and Drug Administration (FDA) has approved PADCEV plus Keytruda as the first and only platinum-free neoadjuvant and adjuvant treatment for adults with Muscle-Invasive Bladder Cancer (MIBC), regardless of cisplatin eligibility.

Antibody Drug Conjugate (ADC) | 13/07/2026 | By News Bureau |  107

Glenmark Advances Phase 3 Trial of Trastuzumab Rezetecan in Ovarian Cancer

Glenmark has advanced the phase 3 clinical trial of trastuzumab rezetecan for platinum-resistant ovarian cancer, with India becoming the first licensed market to approve the study extension.

Antibody Drug Conjugate (ADC) | 02/07/2026 | By News Bureau

US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy

The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).

Antibody Drug Conjugate (ADC) | 26/06/2026 | By News Bureau |  196

Shilpa Biologicals Commissions ADC Drug Substance GMP Facility in India

Shilpa Biologicals has launched an integrated Antibody Drug Conjugate (ADC) drug substance GMP facility in India, expanding Shilpa Medicare’s 25+ years of expertise in highly potent compound manufacturing.

Antibody Drug Conjugate (ADC) | 26/06/2026 | By News Bureau

Mabwell Presents Clinical Data for Nectin-4 ADC 9MW2821 at ESMO 2026

Clinical studies presented at the 2026 ESMO Gynecological Cancers Congress showed that Mabwell’s Nectin-4-targeting ADC 9MW2821 demonstrated a manageable safety profile, promising efficacy, and notable survival benefits in cervical cancer patients, with encouraging antitumor activity when combined with a PD-1 inhibitor.

Antibody Drug Conjugate (ADC) | 20/06/2026 | By News Bureau |  176

Zai Lab Secures EMA Orphan Drug Status for Zoci in Pulmonary Neuroendocrine Carcinomas

Zai Lab has received EMA Orphan Drug Designation (ODD) for zocilurtatug pelitecan (zoci) in pulmonary neuroendocrine carcinomas. The designation recognises promising clinical data suggesting potential benefits over existing therapies for patients with relapsed or refractory extensive-stage Small Cell Lung Cancer (SCLC).

Antibody Drug Conjugate (ADC) | 17/06/2026 | By News Bureau

Merck Doses First Patient in Phase 3 Trial of Investigational ADC for Colorectal Cancer

Merck announces first patient dosing in a phase 3 trial evaluating investigational Antibody Drug Conjugate (ADC) precemtabart tocentecan for metastatic colorectal cancer, targeting CEACAM5 expressed in most colorectal tumors.

Antibody Drug Conjugate (ADC) | 22/05/2026 | By News Bureau |  161

US FDA Approves Enhertu for New Early Breast Cancer Indications

Enhertu receives new US approvals for use before and after surgery in HER2-positive breast cancer, supported by positive DESTINY-Breast11 and DESTINY-Breast05 phase 3 trial results.

Antibody Drug Conjugate (ADC) | 18/05/2026 | By News Bureau |  160